Clinical Trial Update: A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase III clinical trial evaluating rezvilutamide for metastatic hormone-sensitive prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Rezvilutamide (rezvilutamide)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 3 | Status: RECRUITING